{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:55:58Z","timestamp":1775328958174,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.vascn.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T21:18:13Z","timestamp":1545340693000},"page":"15-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology"],"prefix":"10.1016","volume":"96","author":[{"given":"Bernard","family":"Christophe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"William J.","family":"Crumb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vascn.2018.12.004_bb0005","first-page":"iv4","article-title":"Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes","volume":"9","author":"Antzelevitch","year":"2007","journal-title":"Europace"},{"issue":"6","key":"10.1016\/j.vascn.2018.12.004_bb0010","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1517\/14740338.2014.915311","article-title":"Comprehensive in vitro proarrhythmia assay, a novel in vitro\/in silico paradigm to detect ventricular proarrhythmic liability: A visionary 21st century initiative","volume":"13","author":"Cavero","year":"2014","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.vascn.2018.12.004_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.vascn.2015.06.004","article-title":"CiPA: Ongoing testing, future qualification procedures and pending issues","volume":"76","author":"Cavero","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2018.12.004_bb0020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fphys.2017.00917","article-title":"Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment","volume":"8","author":"Chang","year":"2017","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S1734-1140(13)71486-5","article-title":"Simulation of early after-depolarisation in non-failing human ventricular myocytes: Can this help cardiac safety pharmacology?","volume":"65","author":"Christophe","year":"2013","journal-title":"Pharmacological Reports"},{"issue":"2","key":"10.1016\/j.vascn.2018.12.004_bb0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.9734\/BJPR\/2015\/17850","article-title":"In silico study of transmural dispersion of repolarisation in non-failing human ventricular myocytes: Contribution to cardiac safety pharmacology","volume":"7","author":"Christophe","year":"2015","journal-title":"British Journal of Pharmaceutical Research"},{"key":"10.1016\/j.vascn.2018.12.004_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.vascn.2017.09.121","article-title":"Impact of disease state on arrhythmic event detection using APD modelling","volume":"88","author":"Crumb","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2018.12.004_bb0040","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2018.12.004_bb0045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005344-198403000-00015","article-title":"Cardiac effect of cibenzoline","volume":"6","author":"Dangman","year":"1984","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","article-title":"The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance","volume":"159","author":"Darpo","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0055","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fphys.2017.00616","article-title":"Optimization of an in silico cardiac cell model for proarrhythmia risk assessment","volume":"8","author":"Dutta","year":"2017","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pbiomolbio.2017.02.007","article-title":"Electrophysiological properties of computational human ventricular cell action potential models under acute ischemic conditions","volume":"129","author":"Dutta","year":"2017","journal-title":"Progress in Biophysics and Molecular Biology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0065","article-title":"Optimization of an in silico cell model for proarrhythmia risk assessment","volume":"43","author":"Dutta","year":"2016","journal-title":"Computing in Cardiology"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2015","journal-title":"Journal of Biomolecular Screening"},{"issue":"2","key":"10.1016\/j.vascn.2018.12.004_bb0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pbiomolbio.2016.06.003","article-title":"Rabbit-specific computational modelling of ventricular cell electrophysiology: Using populations of models to explore variability in the response to ischemia","volume":"121","author":"Gemmell","year":"2016","journal-title":"Progress in Biophysics and Molecular Biology"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FJC.0b013e3181ffe8b3","article-title":"Electrophysiological properties of HBI-3000: A new antiarrhthymic agent with multiple-channel blocking properties in human ventricular myocytes","volume":"57","author":"Guo","year":"2011","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"8","key":"10.1016\/j.vascn.2018.12.004_bb0085","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.hrthm.2008.05.006","article-title":"QT prolongation is an unreliable predictor of ventricular arrhthymia","volume":"5","author":"Hondeghem","year":"2008","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40264-017-0584-4","article-title":"Drug-induced QT prolongation and torsades de pointes: An all-exclusive relationship or time for an amicable separation?","volume":"41","author":"Hondeghem","year":"2018","journal-title":"Drug Safety"},{"issue":"5","key":"10.1016\/j.vascn.2018.12.004_bb0095","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0735-1097(83)80226-5","article-title":"Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients","volume":"2","author":"Kay","year":"1983","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1016\/j.vascn.2018.12.004_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/bcp.12296","article-title":"Replacing the thorough QT study: Reflections of a baby in the bath water","volume":"78","author":"Kleiman","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1016\/j.vascn.2018.12.004_bb0105","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/hc0902.104711","article-title":"Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmia: Tridimentional mapping of activation of recovery patterns","volume":"105","author":"Kozhevnikov","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.vascn.2018.12.004_bb0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0009-9236(95)90038-1","article-title":"Pharmacokinetic and pharmacodynamic modelling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarisation","volume":"57","author":"Le Coz","year":"1995","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.vascn.2018.12.004_bb0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/14740338.2015.989210","article-title":"Cardiac risks associated with antibiotics: Azithromycin and levofloxacin","volume":"14","author":"Lu","year":"2014","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12012-017-9417-z","article-title":"Amitryptiline may have possibility to induce Brugada syndrome rather than long QT syndrome","volume":"18","author":"Lubna","year":"2017","journal-title":"Cardiovascular Toxicology"},{"issue":"5","key":"10.1016\/j.vascn.2018.12.004_bb0125","doi-asserted-by":"crossref","first-page":"H2006","DOI":"10.1152\/ajpheart.00694.2011","article-title":"High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents","volume":"301","author":"Ma","year":"2011","journal-title":"The American Journal of Physiology \u2013 Heart and Circulatory Physiology"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00129784-200303010-00004","article-title":"Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction","volume":"3","author":"Mah\u00e9","year":"2003","journal-title":"American Journal of Cardiovascular Drugs: Drugs, Devices and Other Interventions"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0135","doi-asserted-by":"crossref","first-page":"F3","DOI":"10.1136\/fn.82.1.F3","article-title":"Should cisapride have been \u201cblacklisted\u201d?","volume":"82","author":"Markiewicz","year":"2000","journal-title":"Archives of Disease in Childhood. Fetal and Neonatal Edition"},{"issue":"6","key":"10.1016\/j.vascn.2018.12.004_bb0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jelectrocard.2017.08.011","article-title":"Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhthymic risk prediction: Are we ready?","volume":"50","author":"Mason","year":"2017","journal-title":"Journal of Electrocardiology"},{"issue":"6","key":"10.1016\/j.vascn.2018.12.004_bb0145","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1039\/C7TX00141J","article-title":"Early afterdepolarisation tendency as a simulated pro-arrhthymic risk indicator","volume":"6","author":"McMillan","year":"2017","journal-title":"Toxicological Research"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk","volume":"91","author":"Mirams","year":"2011","journal-title":"Cardiovascular Research"},{"issue":"3","key":"10.1016\/j.vascn.2018.12.004_bb0155","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.vascn.2014.07.002","article-title":"Prediction of thorough QT study results using action potential simulations based on ion channel screens","volume":"70","author":"Mirams","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2018.12.004_bb0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1749-6632.2011.06324.x","article-title":"Is it time for in silico simulation of drug cardiac side effects?","volume":"1245","author":"Mirams","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.vascn.2018.12.004_bb0165","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1253\/circj.CJ-14-0905","article-title":"Genetic and clinical advances in congenital long QT syndrome","volume":"78","author":"Misuzawa","year":"2014","journal-title":"Circulation Journal"},{"issue":"4","key":"10.1016\/j.vascn.2018.12.004_bb0170","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0002-8703(85)90646-5","article-title":"Antiarrhthymic effects of cibenzoline","volume":"109","author":"Miura","year":"1985","journal-title":"American Heart Journal"},{"issue":"9","key":"10.1016\/j.vascn.2018.12.004_bb0175","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jacc.2003.06.004","article-title":"Ventricular arrhthymia induced by sodium channel blocker in patients with Brugada syndrome","volume":"42","author":"Morita","year":"2003","journal-title":"Journal of American College of Cardiology"},{"issue":"5","key":"10.1016\/j.vascn.2018.12.004_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002061","article-title":"Simulation of the undiseased human cardiac ventricular action potential: Model formulation and experimental validation","volume":"7","author":"O'Hara","year":"2011","journal-title":"PLoS Computational Biology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0185","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3389\/fphar.2017.00816","article-title":"Novel two-step classifier for torsades de pointes risk stratification from direct features","volume":"8","author":"Parikh","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0190","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fphys.2017.00668","article-title":"Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity","volume":"8","author":"Passini","year":"2017","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.yjmcc.2015.09.003","article-title":"Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy","volume":"96","author":"Passini","year":"2016","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"5 Pt 1","key":"10.1016\/j.vascn.2018.12.004_bb0200","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0002-8703(99)70029-3","article-title":"Effect of dofetilide on survival in patients with supraventricular arrhythmias","volume":"138","author":"Pritchett","year":"1999","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cvr\/cvt104","article-title":"Early afterdepolarisation in cardiac myocytes: Beyond reduced repolarisation reserve","volume":"99","author":"Qu","year":"2013","journal-title":"Cardiovascular Research"},{"issue":"6","key":"10.1016\/j.vascn.2018.12.004_bb0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5414\/CPP40241","article-title":"A post-marketing observational study to assess the safety of mibefradil in the community in England","volume":"40","author":"Riley","year":"2002","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2018.12.004_bb0215","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1380.029","article-title":"Modeling cardiac ischemia","volume":"1080","author":"Rodriguez","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1016\/j.vascn.2018.12.004_bb0220","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the cardiac safety research consortium","volume":"167","author":"Sager","year":"2014","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/europace\/eut214","article-title":"Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany","volume":"16","author":"Sarganas","year":"2014","journal-title":"Europace"},{"issue":"6","key":"10.1016\/j.vascn.2018.12.004_bb0230","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/europace\/eul038","article-title":"Pro-arrhythmic effects of amiodarone and concomitant rate-control medication","volume":"8","author":"Schrickel","year":"2006","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.vascn.2018.12.004_bb0235","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management","volume":"149","author":"Tisdale","year":"2016","journal-title":"Canadian Pharmacists Journal"},{"issue":"1","key":"10.1016\/j.vascn.2018.12.004_bb0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2011.10.108","article-title":"Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease","volume":"166","author":"Torp-Pedersen","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"12","key":"10.1016\/j.vascn.2018.12.004_bb0245","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","article-title":"Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danih investigations of arrhythmia and mortality on dofetilide study group","volume":"341","author":"Torp-Pedersen","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.vascn.2018.12.004_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032659","article-title":"Simulation and mechanistic investigation of the arrhythmogenic role of the late sodium current in human heart failure","volume":"7","author":"Trenor","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vascn.2018.12.004_bb0255","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.hrthm.2010.09.017","article-title":"Early afterdepolarisation and cardiac arrhthymias","volume":"7","author":"Weiss","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.vascn.2018.12.004_bb0260","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drudis.2016.09.027","article-title":"Am I or Am I not proarrhthymic? Comparison of various classifications of drug TdP propensity","volume":"22","author":"Wisniowska","year":"2017","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.vascn.2018.12.004_bb0265","author":"Woosley"},{"key":"10.1016\/j.vascn.2018.12.004_bb0270","author":"Woosley"},{"key":"10.1016\/j.vascn.2018.12.004_bb0275","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM199607253350416","article-title":"Cisapride and fatal arrhythmia","volume":"335","author":"Wysowski","year":"1996","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.vascn.2018.12.004_bb0280","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1572-0241.2001.03927.x","article-title":"Postmarketing reports of QT prolongation and ventricular arrhthymia in association with cisapride and food and drug administration regulatory actions","volume":"96","author":"Wysowski","year":"2001","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.vascn.2018.12.004_bb0285","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1476-5381.2012.02200.x","article-title":"Computational assessment of drug-induced effects on the electrocardiogram: From ion channel to body surface potentials","volume":"168","author":"Zemzemi","year":"2013","journal-title":"The British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.vascn.2018.12.004_bb0290","first-page":"96","article-title":"Experimental study of the effect of autonomic nervous system on the transmural dispersion of ventricular repolarisation under acute myocardial ischemia in vivo","volume":"22","author":"Zhang","year":"2002","journal-title":"Journal of Huazhong University of Science and Technology, Medical Sciences"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871918307032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871918307032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:14:43Z","timestamp":1775326483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871918307032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":58,"alternative-id":["S1056871918307032"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2018.12.004","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}